Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

EZH2 inhibtion and IFNy treatment of patient derived organoids [ChIP-seq]

ABSTRACT: We report the chromatin landscape of squamous lung cancer patient derived tumoroids treated with EZH2 inhibitor and IFNy

ORGANISM(S): Homo sapiens

PROVIDER: GSE233469 | GEO | 2023/05/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

EZH2 inhibtion and IFNy treatment of patient derived organoids [RNA-seq]

Project description:We report the transcriptomics of squamous lung cancer patient derived tumoroids treated with EZH2 inhibitor and IFNy

2023-06-01 | GSE233468 | GEO

EZH2 inhibtion and IFNy treatment of patient derived organoids [scRNA-Seq]

Project description:We report the transcriptomics of primary murine lung squamous cell carcinomas in mice treated with EZH2 inhibition and anti-PD1

2023-06-01 | GSE233665 | GEO

EZH2 inhibtion and IFNy treatment of patient derived organoids

Project description:EZH2 inhibtion and IFNy treatment of patient derived organoids

| PRJNA976305 | ENA

EZH2 inhibtion and IFNy treatment of patient derived organoids [RNA-seq]

Project description:EZH2 inhibtion and IFNy treatment of patient derived organoids [RNA-seq]

| PRJNA976311 | ENA

EZH2 inhibtion and IFNy treatment of patient derived organoids [ChIP-seq]

Project description:EZH2 inhibtion and IFNy treatment of patient derived organoids [ChIP-seq]

| PRJNA976310 | ENA

EZH2 inhibtion and IFNy treatment of patient derived organoids [scRNA-Seq]

Project description:EZH2 inhibtion and IFNy treatment of patient derived organoids [scRNA-Seq]

| PRJNA977552 | ENA

EZH2 inhibtion and IFNy treatment of patient derived organoids

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-05-31 | GSE233470 | GEO

Affinify Purification of EZH2 and phosphodeficient EZH2 identifies phosphorylation dependent interactions of EZH2

Project description:Overexpression of EZH2 in estrogen receptor negative (ER-) breast cancer promotes metastasis. EZH2 has been mainly studied as the catalytic component of the Polycomb Repressive Complex 2 (PRC2) that mediates gene repression by trimethylating histone H3 at lysine 27 (H3K27me3). However, how EZH2 drives metastasis despite the low H3K27me3 levels observed in ER- breast cancer is unknown. We have shown that in human invasive carcinomas and distant metastases, cytoplasmic EZH2 phosphorylated at T367 is significantly associated with ER- disease and low H3K27me3 levels. Here, we explore the interactome of EZH2 and of a phosphodeficient mutant EZH2_T367A. We identified novel interactors of EZH2, and identified interactions that are dependent on the phosphorylation and cellular localization of EZH2 that may play a role in EZH2 dependent metastatic progression.

2018-07-03 | PXD010073 | Pride

Expression data from patient-derived pancreatic cancer organoids with gene engineering

Project description:Lineage plasticity often emerges in human cancer along with clinical progression and exposure to chemotherapy. Although lineage transition is evident in an aggressive subtype of human pancreatic cancer characterized by the loss of the ductal identity and manifestation of squamous cell-like features, the drivers of these processes have remained elusive. We here harmonized organoid technology, molecular profiling and gene engineering and found that the H3K27me3-mediated erasure of the ductal identity and lineage specifiers, and hijacking of the TP63-driven squamous-cell program provide environmental fitness. Induction and fixation of the squamous-cell identity was dependent on Wnt-deficient environment, whereas KDM6A loss or a hypoxic niche licensed tumor cells for squamous reprogramming. EZH2 inhibition counterbalanced the epigenetic bias and curbed the growth of pancreatic cancer organoids with squamous features. Our results demonstrate how adversarial microenvironment dictates the molecular and histological evolution of human pancreatic cancer, and provide insights into the principles and significance of lineage conversion in human cancer. We used microarray gene expression analysis to study the effect of delta-Np63 overexpression and TP63 knockout in patient-derived pancreatic cancer organoids or genetically engineered organoids.

2024-06-30 | GSE263236 | GEO

RNA-seq analysis of IL-17A+/IFNy+ CD8+ and IL-17A+CD4+ T cells from Psoriatic Arthritis Synovial Fluid

Project description:Psoriatic arthritis is a seronegative polyarticular form of inflammatory arthritis . Genetic analysis implicates a role for both IL-17/23 axis and CD8+ T cells in disease susceptibility. Using RNA-seq we identified differential gene expression between synovial IL-17A+(IFNy+/-) CD8+ T cells compared to IL-17A-IFNy+ CD8+ T cells and IL-17A+CD4+ T cells from the synovial fluid of psoriatic arthritis patients. We find that IL-17A+CD8+ T cells have a transcriptional overlap with IL-17A+CD4+ T cells. Overall we show these IL-17A+ CD8+ T cells have a polyfunctional, pro-inflammatory capacity and are potentially derived from common precursors, shared with IL-17A-CD8+ T cells.

2020-04-17 | GSE137510 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data